FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
latest-news-card-1
Biologics

Prasad Reassumes Chief Medical/Scientific Officer Role

FDA commissioner Marty Makary reinstates CBER director Vinay Prasads previous additional duties as the agencys chief medical and scientific officer.

latest-news-card-1
Human Drugs

Expanded Approval for AZs Koselugo

FDA approves an expanded indication to include pediatric patients aged one and older for AstraZenecas Koselugo to treat some cases of neurofibromatosi...

latest-news-card-1
Human Drugs

Non-Opioid Analgesic Development Guidance

FDA publishes a draft guidance to assist in developing non-opioid analgesics to treat chronic pain.

Medical Devices

Apollo TMS Cleared for Depressed Adolescents

FDA clears a new indication for neurocare groups Apollo TMS therapy device to treat adolescents with major depressive disorder.

latest-news-card-1
Human Drugs

FDA Approves J&Js New Bladder Cancer Therapy

FDA approves a Johnson & Johnson NDA for Inlexzo (gemcitabine intravesical system) for adults with non-muscle invasive bladder cancer who do not respo...

latest-news-card-1
Human Drugs

Greenwich Gets Fast Track for Breast Cancer Therapy

FDA grants Greenwich LifeSciences fast track status for GLSI-100 for preventing breast cancer recurrences.

FDA General

FDA Orders Crackdown on Misleading Prescription Drug Ads

In a new crackdown on drug advertising, FDA orders pharmaceutical companies to remove any noncompliant ads and bring all promotional communications in...

Human Drugs

FDA Accepts Corcept Relacorilant NDA

FDA accepts a Corcept NDA for its relacorliant as a treatment for patients with platinum-resistant ovarian cancer.

latest-news-card-1
FDA General

FDA Digital Health Leader Leaves for Mayo Clinic

Former FDA Digital Health Center of Excellence acting director Sonja Fulmer leaves the agency to accept a position at Mayo Clinic as senior director o...

latest-news-card-1
Human Drugs

Lexicon Submits New Data on Stalled Diabetes Drug

Lexicon Pharmaceuticals submits new clinical data to FDA that attempts to advance its stalled NDA for its diabetes drug Zynquist (sotagliflozin).